Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

NuVasive Inc. stock is showing signs of recovery from deep slump occurred earlier this month. The stock is likely to have factored in the impact of its weak financial numbers for the third quarter. Aegis has started its coverage of the stock with Buy rating. The stock has been given the target price of $72. It is currently trading close to $65. 14 out of the 17 analysts covering the company have Buy rating for the stock.
NuVasive Inc. had announced the downward revision of its guidance. The company now expects its full year revenue to be $952 million, while its earlier guidance stood at $962 million. For its full year earnings, NuVasive expects the figure to be at $1.64 per share, lower than consensus estimates.

Fluidigm Corporation ($FLDM) stock jumped over 6% in its last trading session. It has shown remarkable recovery from the slump witnessed in the month of October. The company recently announced that its Board of Directors has adopted a Tax Benefit Preservation Plan. The plan will help to preserve the significant potential long-term tax benefit associated with Fluidigm’s net operating loss carryforwards. The company will seek stockholder approval of the plan at its 2017 annual meeting of stockholders.
Earlier this month, Fluidigm Corporation had also announced the introduction of a modular set of high-parameter Maxpar® mass cytometry panels for immuno-oncology research. The set is designed to work with Helios™ and CyTOF® systems.


• Novo Nordisk's ($NVO) long-term study of the safety of Tresiba (insulin degludec injection) vis a vis insulin glargine U100 when added to standard of care met the primary endpoint of demonstrating non-inferiority in terms of major cardiovascular events (MACE). The final results are in line with the interim data submitted by the company to the FDA in 2015.
• Abbott's ($ABT) announced the receipt of CE Mark certification for its hand-held blood testing platform i-STAT Alinity System. The portable device uses only a few drops of blood to perform a range of diagnostic tests. The product is now commercially available in Europe and other countries that recognize CE Mark.

• Pfizer ($PFE) announced that a Phase 3 clinical trial of REFLECTIONS B3271002, comparing the safety and efficacy of biosimilar PF-05280014 to Roche's ($RHHBY) Herceptin (trastuzumab) met the primary endpoint. The trial showed equivalence, measured by objective response rate (ORR), taken in combination with paclitaxel, in first-line patients with HER-positive metastatic breast cancer.
• Bluebird bio ($BLUE) announced the positive interim results from a Phase 1 study assessing CAR-T candidate bb2121 in patients with treatment-resistant multiple myeloma (MM).


• Evotec AG ($EVOTF)and Merck KGaA's ($MKGAF) life sciences unit signed a set of collaboration agreements for the purpose of discovering new therapeutic targets. Financial terms of the deal were not disclosed.


• Ascendis Pharma ($ASND) reported its third quarter loss at $18.3 million euro or euro 0.72 in loss per share. Its quarterly revenue declined 45% on Year over Year basis to euro 1.16 million.

• Nivalis Therapeutics ($NVLS) received rating downgrade from Robert Baird. Its new rating if Neutral while its target price has been slashed from $29 to $3.
• Arbutus Biopharma ($ABUS) received earnings upgrade to Buy from Neutral by Chardan Capital. It also received $1 boost in the price target to $4 (39% upside).

Gainers (% price change) Last Trade Change Mkt Cap
Fluidigm Corporation
6.43 +0.38 (6.28%) 186.31M
Derma Sciences Inc
4.80 +0.20 (4.35%) 135.69M
AcelRx Pharmaceuticals
3.10 +0.10 (3.33%) 140.53M
Zeltiq Aesthetics Inc
44.01 +1.20 (2.80%) 1.79B
Novo Nordisk A/S (ADR)
33.60 +0.88 (2.69%) 68.23B
Losers (% price change)
Dynavax Tech. Corp.
4.30 -0.45 (-9.47%) 171.07M
Amicus Therapeutics, Inc.
5.98 -0.53 (-8.14%) 665.95M
Valeant Pharmaceuticals
15.79 -1.37 (-7.98%) 5.30B
Insys Therapeutics Inc
11.79 -1.00 (-7.82%) 857.57M
Sarepta Therapeutics Inc
34.26 -2.46 (-6.70%) 1.89B
Most Actives (dollar volume)
Johnson & Johnson
111.30 -1.18 (-1.05%) 301.06B
Pfizer Inc.
32.14 +0.22 (0.69%) 197.39B
UnitedHealth Group Inc
158.32 +1.36 (0.86%) 156.12B
Bristol-Myers Squibb Co
56.44 +0.07 (0.13%) 94.07B
Medtronic PLC
73.01 -0.41 (-0.56%) 100.90B